Key Insights

Highlights

Success Rate

92% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

2.9%

1 terminated out of 34 trials

Success Rate

92.3%

+5.8% vs benchmark

Late-Stage Pipeline

6%

2 trials in Phase 3/4

Results Transparency

17%

2 of 12 completed with results

Key Signals

2 with results92% success

Data Visualizations

Phase Distribution

17Total
Not Applicable (6)
P 1 (1)
P 2 (8)
P 3 (1)
P 4 (1)

Trial Status

Completed12
Unknown7
Recruiting6
Active Not Recruiting3
Not Yet Recruiting3
Withdrawn2

Trial Success Rate

92.3%

Benchmark: 86.5%

Based on 12 completed trials

Clinical Trials (34)

Showing 20 of 20 trials
NCT07517250Not Yet RecruitingPrimary

A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients

NCT07439341Not Yet RecruitingPrimary

AGE and CALLY Index in Familial Mediterranean Fever

NCT07130305Not ApplicableRecruitingPrimary

is There an Effect of Adding Body Vibration to Intake of Vitamin D on Some Outcomes of Familial Mediterranean Fever

NCT07129538Not ApplicableRecruitingPrimary

Outcomes of Inspiratory Muscle Training in FMF Adolescents

NCT07130318Not ApplicableRecruitingPrimary

Mediterranean Diet in Familial Mediterranean Fever: Is Fatty Liver Affected by Addition of Aerobic Exercise

NCT07128225Active Not RecruitingPrimary

Health-related Quality of Life, Electrocardiographic and Holter Findings in Children With Familial Mediterranean Fever

NCT06338891RecruitingPrimary

Can Gluten/Wheat or Other Foods be Responsible for FMF Attacks

NCT06697028Completed

Assessment of Cardiorespiratory Fitness Using the PACER in Patients With Juvenile Idiopathic Arthritis and Familial Mediterranean Fever

NCT06981520Not Yet RecruitingPrimary

Caspase-1 Activity, IL-1beta, and IL-18 in Patients With FMF

NCT06923124CompletedPrimary

A Study to Describe a Group of Spanish Patients With FMF and to Identify Suboptimally Treated Patients With Minimal Disease Activity and Its Impact on Quality of Life

NCT05190991Phase 2RecruitingPrimary

Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever

NCT05092776Phase 2Active Not RecruitingPrimary

Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine

NCT04478409RecruitingPrimary

Characterization of a Functional Test for Mediterranean Family Fever Screening - 2

NCT01059279TerminatedPrimary

Heat Intolerance in the Group of FMF Patients

NCT01705756Phase 3CompletedPrimary

Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever

NCT06257342Active Not RecruitingPrimary

Physical Abilities of Teenagers With Familial Mediterranean Fever

NCT06033339Not ApplicableUnknownPrimary

Assessment of microRNAs Role in Familial Mediterranean Fever FMF Pathophysiology

NCT06034795UnknownPrimary

Evaluation of Bone Metabolism in Children and Adolescents With Familial Mediterranean Fever

NCT05448391Phase 2WithdrawnPrimary

A Study to Evaluate RIST4721 in Familial Mediterranean Fever (FMF)

NCT05177120CompletedPrimary

Central Sensitization in Familial Mediterranean Fever (FMF)

Scroll to load more

Research Network

Activity Timeline